Upcoming Events

Current and future events

Current and Emerging Biomarkers to Advance Clinical Research in Parkinson’s Disease

Parkinson’s disease biomarker research continues to advance with the objectives of enabling earlier detection of neurodegeneration, elucidating disease mechanisms, identifying potential therapeutic targets as well as monitoring disease progression. While many promising biomarkers have been proposed, the ideal biomarker — with adequate sensitivity or specificity — remains elusive.

From α-synuclein to advanced magnetic resonance imaging (MRI) techniques, this webinar will cover both traditional Parkinson’s disease biomarkers and the potential utility of emerging biomarkers, such as microRNA (miRNA), microbiome and multimodal approaches.

Citing longitudinal research studies and recent clinical trials, the featured speakers will share the potential utility of fluid-based biomarkers and imaging biomarkers, discussing how each may help track drug efficacy and advance clinical trials.

Join this webinar to learn how fluid and imaging biomarkers can impact study design and patient selection in Parkinson’s disease clinical trials.

-Robert Martone, Associate Director, Labcorp Drug Development
-Hiba Kazmi, PhD, Biomarker Scientist, IXICO
-Antoniya Todorova, MD, PhD, Medical Director, Labcorp

MDS 2022 - International Congress of Parkinson’s Disease and Movement Disorders

The International Parkinson and Movement Disorder Society (MDS) is a professional society of clinicians, scientists, and other healthcare professionals who are interested in Parkinson’s disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control.


Amsterdam, The Netherlands will play host to the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, or ECTRIMS 2022, on October 26–28.